NCT03965975

Brief Summary

The objectives of the Clinical Validation Through Analytical Study With Urine Samples to Compare the Effectiveness and Security of an Intelligent Device are: 1.To evaluate the performance of S-There Device in comparison to the golden standard used in the lab.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
700

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jun 2019

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 24, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

May 29, 2019

Completed
12 days until next milestone

Study Start

First participant enrolled

June 10, 2019

Completed
9 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2020

Completed
Last Updated

December 5, 2019

Status Verified

December 1, 2019

Enrollment Period

9 months

First QC Date

May 24, 2019

Last Update Submit

December 4, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • Accuracy to compared device

    The primary objective of the study is to evaluate the accuracy of the S-There device compared to the Lab gold standards, for each analyte.

    Through study completion, an average of 1 month

Study Arms (1)

All participants (single arm)

OTHER

All study participants once enrolled into the study were asked to collect their midstream urine in the designated urine cups. The urine sample was then sent the Lab and tested sequentially; first by the golden standard techniques used by the Lab (first intervention) and by the S-There device (comparative device - second intervention).

Device: Lab Gold StandardDevice: S-There

Interventions

First intervention (assigned to the "All participants" arm).

All participants (single arm)
S-ThereDEVICE

Second intervention (assigned to the "All participants" arm).

All participants (single arm)

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients who came to the emergency room, primary care and nephrology unit.

You may not qualify if:

  • Subject cannot collect urine in receptacle.
  • Urinary Catheter

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital de Cruces

Barakaldo, Bizkaia, 48903, Spain

RECRUITING

MeSH Terms

Conditions

Renal Insufficiency, ChronicHeart FailureDiabetes MellitusKidney DiseasesHematuriaUrinary Tract Infections

Condition Hierarchy (Ancestors)

Renal InsufficiencyUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsHeart DiseasesCardiovascular DiseasesGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesUrination DisordersHemorrhageInfections

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 24, 2019

First Posted

May 29, 2019

Study Start

June 10, 2019

Primary Completion

March 1, 2020

Study Completion

March 1, 2020

Last Updated

December 5, 2019

Record last verified: 2019-12

Locations